Enveric Biosciences, Inc. (ENVB) |
|
2.87 0.01 (0.35%)
|
01-27 15:59 |
|
Open: |
2.78 |
Pre. Close: |
2.86 |
|
High:
|
2.955 |
Low:
|
2.78 |
|
Volume:
|
28,172 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:44:10 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.59 One year: 4.2 |
| Support: |
Support1: 2.14 Support2: 1.57 |
| Resistance: |
Resistance1: 3.07 Resistance2: 3.59 |
| Pivot: |
2.77 |
| Moving Average: |
MA(5): 2.84 MA(20): 2.67
MA(100): 3.42  MA(250): 8.51 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 69.4 %D(3): 71.8 |
| RSI: |
RSI(14): 58.1 |
| 52-week: |
High: 34.34 Low: 0.18 |
| Average Vol(K): |
3-Month: 46 (K) 10-Days: 37 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ENVB ] has closed below upper band by 23.2%. Bollinger Bands are 74.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.96 - 2.97 |
2.97 - 2.98 |
|
Low:
|
2.75 - 2.76 |
2.76 - 2.78 |
|
Close:
|
2.85 - 2.87 |
2.87 - 2.89 |
|
Company Description |
|
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida. |
Headline News |
Sat, 28 Jan 2023
TDR's Top 5 Psychedelic Developments For The Week Of January 23 - The Dales Report
Thu, 12 Jan 2023
How Will the Market React to Enveric Biosciences Inc (ENVB) Stock Getting a Neutral Rating - InvestorsObserver
Wed, 21 Dec 2022
Enveric Biosciences to Present at the 6th Annual Neuroscience ... - Business Wire
Mon, 28 Nov 2022
Enveric Biosciences Announces Confidential Submission of ... - Business Wire
Mon, 24 Oct 2022
Enveric Biosciences Advances Lead Candidate for the Treatment of ... - Business Wire
Tue, 30 Aug 2022
7 Psychedelics Stocks to Buy for a Big Drug Boom - InvestorPlace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
9.6 (%) |
|
% Held by Institutions
|
7.1 (%) |
|
Shares Short
|
46 (K) |
|
Shares Short P.Month
|
43 (K) |
Stock Financials |
|
EPS
|
-1.67 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
10.98 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-33.4 |
|
Return on Equity (ttm)
|
-131.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-12.7 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-18 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-1.73 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.26 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.34 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-11-24 |
|
Ex-Dividend Date
|
2008-04-22 |
|
Your Ad Here
|
|
